Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Jounce Therapeutics, Inc. (JNCE)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
6.17+0.16 (+2.66%)
At close: 04:00PM EST
6.08 -0.09 (-1.46%)
After hours: 05:57PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close6.01
Open5.91
Bid6.08 x 1400
Ask7.29 x 800
Day's Range5.91 - 6.36
52 Week Range5.03 - 14.84
Volume348,655
Avg. Volume414,050
Market Cap316.173M
Beta (5Y Monthly)1.05
PE Ratio (TTM)N/A
EPS (TTM)-0.54
Earnings DateFeb 23, 2022 - Feb 28, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est15.40
  • GlobeNewswire

    Jounce Therapeutics to Present at Upcoming Investor Conferences in January

    CAMBRIDGE, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that company management will participate at the following upcoming investor conferences in January: H.C. Wainwright BioConnect Virtual Conference: Presentation will be available for on-demand viewing starting on January 10, 2022 at 7:00 a.m. ET.40th Annual J.P. Mor

  • Benzinga

    Notable Jounce Therapeutics Insider Makes $15M Sale

    Mark Levin, Insider at Jounce Therapeutics (NASDAQ:JNCE), made a large insider sell on November 12, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Friday showed that Levin sold 1,900,000 shares of Jounce Therapeutics at a price of $8.38. The total transaction amounted to $15,922,000. Following the transaction, Levin still owns 1,432,638 shares of the company, worth $12,678,846. Jounce Therapeutics shares are trading down 1.67% at

  • GlobeNewswire

    Jounce Therapeutics to Present at Upcoming Investor Conferences in November

    CAMBRIDGE, Mass., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that company management will participate at the following upcoming investor conferences in November: 5th Annual Cowen IO Next Summit: Fireside chat on Monday, November 15, 2021 at 10:45 a.m. ET.33rd Annual Piper Sandler Healthcare Conference: Fireside chat availabl

Advertisement
Advertisement